# Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

> **NCT03921879** · PHASE1 · UNKNOWN · sponsor: **Oncotartis, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma, T-Cell
- Lymphoma, Follicular
- Lymphoma, Peripheral T-Cell
- Lymphoma, Hodgkin

## Interventions

- **DRUG:** OT-82 Dose Escalation
- **DRUG:** OT-82 Dose Expansion

## Key facts

- **NCT ID:** NCT03921879
- **Lead sponsor:** Oncotartis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-29
- **Primary completion:** 2021-04
- **Final completion:** 2021-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03921879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03921879, "Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03921879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*